ViewsML and Dartmouth Hitchcock Medical Center Partner to Advance AI-Driven Virtual Biomarkers and Diagnostics

ViewsML's AI technology joins Dartmouth Hitchcock Medical Center's clinical expertise to create virtual biomarkers that transform pathology diagnostics

VANCOUVER, BRITISH COLUMBIA, CANADA, April 8, 2025 /EINPresswire.com/ -- Techbio innovator ViewsML is proud to announce a strategic collaboration with the Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center (DHMC), a leading tier 1 academic medical institution. This partnership leverages DH's extensive tissue repository, digital pathology systems, and wet lab infrastructure to accelerate the development of ViewsML's groundbreaking virtual biomarkers and diagnostics.

This collaboration marks a significant advancement in ViewsML's vision to revolutionize precision medicine through AI-driven virtual diagnostics. By combining DH's clinical and digital pathology expertise with ViewsML's proprietary AI technologies, the partnership aims to deliver scalable virtual diagnostic solutions.

Transforming Histopathology with Virtual Immunohistochemistry (IHC) Staining

The partnership will focus on developing virtual biomarkers using ViewsML's virtual IHC staining platform, reducing the dependence on traditional physical antibodies and immunostaining while improving turnaround times. Leveraging DH's vast clinical resources, ViewsML will create virtual biomarker panels that provide researchers and clinicians with novel cell-level insights from a single H&E whole slide image. This technology has the potential to revolutionize spatial proteomics, enhance patient selection for clinical trials, and improve risk stratification for clinical diagnostics and precision medicine.

"This collaboration is pivotal," said Dr. Kenneth To, CEO of ViewsML. "DH's prestigious reputation as a leader in patient care, research, and education, coupled with its forward-looking adoption of digital pathology, aligns perfectly with our vision. Together, we will redefine AI’s role in biomarker virtualization, staining, and diagnostics to enhance patient outcomes."

Empowering Precision Diagnostics Through AI

"Dartmouth Hitchcock Medical Center has been at the forefront of advancing healthcare with cutting-edge research and innovation, and this partnership further emphasizes that point," remarked Dr. Arief Suriawinata, Interim Chair for the Department of Pathology and Laboratory Medicine at DH. "ViewsML's transformative AI platform represents a leap forward for both research and clinical care. We are thrilled to collaborate with ViewsML to harness AI's full potential in creating the next generation of precision diagnostics."

ViewsML's platform transforms the traditional immunohistochemistry (IHC) and immunofluorescence (IF) workflow, offering instant per-cell spatial and quantitative biomarker expression prediction from a single digital H&E image. This AI-driven approach saves time, costs, and rare precious tissue whilst providing richer data sets through virtual multiplexing.

About ViewsML

ViewsML is a techbio company transforming precision medicine and diagnostics through virtual biomarkers. Its core platform virtualizes antibodies and immunostaining to predict biomarker expression at the single-cell level, both spatially and quantitatively, reducing a days-long process to mere minutes. This innovation enables superior drug characterization, precise patient stratification in clinical trials, and the virtualization of diagnostic assays for precision medicines.

About Dartmouth Hitchcock Medical Center

Dartmouth Health, New Hampshire’s only academic health system and the state’s largest private employer, serves patients across northern New England. Dartmouth Health provides access to more than 2,000 providers in almost every area of medicine, delivering care at its flagship hospital, Dartmouth Hitchcock Medical Center (DHMC) in Lebanon, NH, as well as across its wide network of hospitals, clinics and care facilities. DHMC is consistently named the #1 hospital in New Hampshire by U.S. News & World Report, and is recognized for high performance in numerous clinical specialties and procedures. Dartmouth Health includes Dartmouth Cancer Center, one of only 57 National Cancer Institute-designated Comprehensive Cancer Centers in the nation, and the only such center in northern New England; Dartmouth Health Children’s, which includes the state’s only children’s hospital and multiple locations around the region; member hospitals in Lebanon, Keene, Claremont, Hampstead and New Lon
don, NH, and Windsor and Bennington, VT; Visiting Nurse and Hospice for Vermont and New Hampshire; and more than 30 clinics that provide ambulatory and specialty services across New Hampshire and Vermont. Through its historical partnership with Dartmouth and the Geisel School of Medicine, Dartmouth Health trains nearly 400 medical residents and fellows annually, and performs cutting-edge research and clinical trials recognized across the globe with Geisel and the White River Junction VA Medical Center in White River Junction, VT. Dartmouth Health and its more than 16,000 employees are deeply committed to serving the healthcare needs of everyone in our communities and to providing each of our patients with exceptional, personal care.

For media inquiries, please contact:
Kenneth To, PhD, MBA
CEO, ViewsML
kto@viewsml.com

Kenneth To
ViewsML
kto@viewsml.com
Visit us on social media:
X
LinkedIn